Company intelligence / Profile preview
ReqMed Company, Ltd.
Machida-City, Tokyo, Japanreqmed.co.jp ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
The company has successfully developed and commercialized Cystadan® bulk powder (betaine) for homocystinuria, and has conducted multiple Phase II and Phase III clinical trials for various indications including PPS for OsteoArthritis, HTLV-1 Associated Myelopathy, and MucoPolySaccharidosis.
- Therapeutic areas
- Rare DiseasesNeurologyMetabolic DisordersRheumatology
- Modalities
- Small molecule drugsPolymer
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kyowa Hakko Kogyo Co., Ltd.PsychoGenics, Inc.bene pharmaChem GmbH & Co. KGChong Kun Dang Pharmaceutical Corp.Orphan Europe SARLIcahn School of Medicine at Mount Sinai
Beyond the preview
Go deeper on ReqMed Company, Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReqMed Company, Ltd..